Search
EHA Research Mobility Grants
The call for applications is currently closed
EHA strives to develop the career of young scientists by supporting mobility and facilitating a visit to a research group in another institute.
EHA-Baltic Hematology Tutorial on Bleeding Disorders & Thrombosis
Dates: August 28-30, 2020
Location: Riga, Latvia
Chairs: S Eichinger (EHA) & S Lejniece (LASH)
After a successful first edition, EHA is once again collaborating with the Latvian Society of Hematology (LASH), the Estonian Society of Hematology (EHS) and the Lithuanian Society of Hematology…
Highlights of Past EHA (HOPE) Asia 2020
EHA is returning to Sri Lanka for the 2nd edition of the Highlights of Past EHA (HOPE) Asia, organized with our hosting partner: the Sri Lanka College of Haematologists (SLCH).
Read moreHighlights of Past EHA (HOPE) Latin America 2020
EHA and the Argentinian Society of Hematology (SAH) are very happy to announce that the Highlights of Past EHA (HOPE) Latin America 2020 will take place on November 13, 2020 in a virtual format.
Read moreHighlights of Past EHA (HOPE) Asia 2021
For the third edition of the Highlights of Past EHA (HOPE) Asia, EHA will organize a truly regional meeting by collaborating simultaneously with our hematology partners from the region.
Read moreEHA-SAH Hematology Tutorial on Acute Leukemia, MDS and BMF
Dates: September 11-12, 2020
Location: Buenos Aires, Argentina
Chairs: G Stemmelin, G Ossenkoppele
The third EHA-SAH Hematology Tutorial will be held in Buenos Aires, Argentina.
EHA-Balkan Hematology Day 2025
The EHA-Balkan Hematology Day is a two-day meeting jointly organized by the European Hematology Association, the Macedonian Hematology Association, and the Macedonian Academy of Sciences and Arts.
Read moreGrants & abstract awards
EHA Travel GrantsThe call for travel grant applications closed on March 1, 2025 (23:59 CET). The grants will only be available for investigators with accepted abstracts, submitted during the regular abstract submission.
Read moreSelected EMA news
March 2025New medicines recommended for approval
Lynozyfic (linvoseltamab)
Treatment of refractory multiple myeloma (a cancer of the bone marrow)
New information on approved medicines
Calquence (acalabrutinib) - new indication
Treatment of blood cancer
Columvi (glofitamab) - new indication
Treatment of blood cancer
Darzalex (daratumumab) - change of indication
Treatment…
Community and Stakeholder Committee call for interest
The Community and Stakeholder Committee (CSC) serves as an advisory body to the EHA Board and works closely with the EHA Office and other committees.
Read more